DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC?
Автор: Breast Cancers Today
Загружено: 2025-06-05
Просмотров: 289
In this update from ASCO 2025, Dr. Maryam Lustberg, Chief of Breast Medical Oncology at Yale Cancer Center, breaks down the DESTINY-Breast09 trial and what it means for the evolving first-line treatment of HER2-positive metastatic breast cancer. She discusses the clinical rationale for combining trastuzumab deruxtecan (T-DXd) with pertuzumab, shares key PFS findings compared to the standard THP regimen, and explores safety considerations, including ILD risk. Dr. Lustberg also weighs in on future de-escalation strategies, sequencing decisions, and how this study could influence real-world clinical practice.
View more practical considerations and timely updates straight from the 2025 ASCO Annual Meeting at https://www.docwirenews.com/page/brea....
#ASCO25 #BreastCancer #HER2Positive #TDXd #Oncology #CancerResearch #ADC #MetastaticBreastCancer #PrecisionOncology
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
